ROTH Capital Partners

Jonathan Aschoff, Ph.D., (646) 616-2795
jaschoff@roth.com

Sales (800) 933-6830, **Trading** (800) 933-6820

COMPANY NOTE | EQUITY RESEARCH | December 05, 2022

Healthcare: Biotechnology **Company Update**

Imugene Limited | IMU.AX - $0.19 - ASX | *Buy*

Stock Data	
52-Week Low - High	$0.13 - $0.54
Shares Out. (mil)	6,385.45
Mkt. Cap.(mil)	$1,181.31
3-Mo. Avg. Vol.	23,553,630
12-Mo.Price Target	AUD0.71
Cash (mil)	AUD179.9
Tot. Debt (mil)	AUD0.0

Revenue ($AUD millions)

Yr Jun	—2022—	—2023E—	—2024E—
		Curr	Curr
1Half	0.0A	0.0E	0.0E
2Half	0.0A	0.0E	0.0E
YEAR	0.0A	0.0E	0.0E

EPS $AUD

Yr Jun	—2022—	—2023E—	—2024E—
		Curr	Curr
1Half	(0.00)A	0.00E	-
2Half	(0.00)A	0.00E	-
YEAR	(0.01)A	(0.01)E	(0.01)E



IMU: Favorable Phase 2 HER-Vaxx DoR Data Presented at the ESMO Asia Congress

Although largely the same final OS HERIZON trial results as were released in early 3Q22, IMU's new results in an oral slide presentation at the recent ESMO Asia Congress consist of duration of response (DoR) data being longer in the HER-Vaxx plus SOC chemotherapy (i.e., cisplatin plus either 5FU or capecitabine; or oxaliplatin plus capecitabine) arm than in the chemotherapy alone control arm (30 versus 19 weeks, respectively). The trial enrolled 36 gastric cancer patients.

- Although largely the same final OS HERIZON trial results as were released in early 3Q22, IMU's new results in an oral slide presentation at the recent ESMO Asia Congress consist of duration of response (DoR) data being longer in the HER-Vaxx plus SOC chemotherapy (i.e., cisplatin plus either 5FU or capecitabine; or oxaliplatin plus capecitabine) arm than in the chemotherapy alone control arm (30 versus 19 weeks, respectively). The trial enrolled 36 gastric cancer patients.

- For comparison, at last report in early 3Q22, IMU released positive final HERIZON trial OS results, a trial that had a pre-specified log-rank one-sided false positive probability of 0.10, and showed a 41.5% survival benefit (Hazard Ratio (HR) of 0.585 (80% 2-sided CI: 0.368, 0.930; p=0.066) for HER-Vaxx plus SOC chemotherapy versus SOC chemotherapy alone, with median OS of 13.9 versus 8.3 months in favor of HER-Vaxx. HER-Vaxx also showed no noteworthy added toxicity when included as part of the combination therapy versus the SOC chemotherapy control.

- We also note that a new higher dose of HER-Vaxx (100µg) has been approved for use in the nextHERIZON (pretreated metastatic HER2 positive gastric cancer) and neoHERIZON (perioperative HER2 positive gastric cancer) trials. HER-Vaxx at 100µg was safe with no dose-limiting toxicities and no serious adverse reactions observed. Recall that the HERIZON trial used doses of 10ug, 30ug, and 50ug, and we expect the 100ug dose to be more effective, but similarly nontoxic compared to the lower HERIZON doses. IMU also has enough HER-Vaxx drug material to complete all of its planned HER-2 positive gastric cancer trials (i.e., nextHERIZON and neoHERIZON).

VALUATION

Our 12-month price target of AUD0.71 is based on a DCF analysis using a 10% discount rate that is applied to all cash flows and the terminal value, which is based on a 5x multiple of our projected FY2031 operating income of about AUD1.4 billion. We arrive at this valuation by projecting future revenue from CHECKvacc in TNBC, HER-Vaxx in advanced HER2+ gastric cancer, and PD1-Vaxx in NSCLC. Commercial success outside these financially modeled programs would serve as potential upside to our valuation.

Factors that could impede shares of Imugene from achieving our price target include any of its three modeled immuno-oncology products failing to succeed clinically. Also, the FDA and foreign regulatory authorities could fail to approve Imugene's products even if their respective pivotal clinical trials succeed, in the event the agency views the results as not clinically meaningful. Loss of key management personnel could also impede achieving our Imugene price target, as could the significant delay of clinical progress from, for example, lasting COVID-19 headwinds.

RISKS

- **Clinical risk.** Imugene's clinical staged products could fail to deliver statistically significant results in late-stage clinical trials, substantially reducing the value of Imugene's product candidates and therefore our target price.
- **Regulatory risk.** Even if successful in the clinic, Imugene's products could fail to be approved by domestic and/or foreign regulatory bodies, which would reduce Imugene's value and therefore our target price.
- **Financing risk.** Imugene will need additional capital to fund its operations, and such financing may not occur or it could be substantially dilutive to existing investors.
- **Competitive risk.** For any future approved Imugene products, they may not be well adopted in a competitive marketplace, which would adversely affect Imugene's value and therefore our target price.
- **High stock price volatility.** This issue is common among small-cap biotechnology companies with relatively low trading volumes.

COMPANY DESCRIPTION

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Imugene Limited
Income Statement
Fiscal Year ends June
(in AUD$000, except per share items)

Jonathan Aschoff, Ph.D. (646) 616-2795
jaschoff@roth.com

	FY2018A	FY2019A	FY2020A	FY2021A	FY1H22	FY2H22	FY2022A	FY1H23E	FY2H23E	FY2023E	FY2024E
CHECKvacc royalty revenue											
HER-Vaxx royalty revenue											
PD1-Vaxx royalty revenue											
Total royalty revenue											
R&D	3,224	7,612	9,364	15,355	13,832	22,780	36,612	24,147	25,596	49,743	57,204
SG&A	2,554	4,777	5,515	10,311	6,690	7,371	14,061	7,740	8,127	15,866	17,135
Total operating expenses	**5,778**	**12,389**	**14,879**	**25,667**	**20,522**	**30,151**	**50,673**	**31,887**	**33,722**	**65,609**	**74,340**
Operating income	**(5,778)**	**(12,389)**	**(14,879)**	**(25,667)**	**(20,522)**	**(30,151)**	**(50,673)**	**(31,887)**	**(33,722)**	**(65,609)**	**(74,340)**
Other income/loss (R&D tax incentive, etc)	1,750	4,205	4,074	7,200	5,313	7,371	12,684	6,000	6,000	12,000	22,024
Finance income/expense net	94	409	297	11	376	(304)	72	100	100	200	210
Net income (pretax)	**(3,934)**	**(7,775)**	(10,508)	**(18,456)**	**(14,833)**	**(23,084)**	**(37,917)**	**(25,787)**	**(27,622)**	**(53,409)**	**(52,106)**
Income tax expense (benefit)											
Net income	**(3,934)**	**(7,775)**	**(10,508)**	**(18,456)**	**(14,833)**	**(23,084)**	**(37,917)**	**(25,787)**	**(27,622)**	**(53,409)**	**(52,106)**
EPS basic	**(0.00)**	**(0.00)**	**(0.00)**	**(0.00)**	**(0.00)**	**(0.00)**	**(0.01)**	**(0.00)**	**(0.00)**	**(0.01)**	**(0.01)**
EPS diluted	**(0.00)**	**(0.00)**	**(0.00)**	**(0.00)**	**(0.00)**	**(0.00)**	**(0.01)**	**(0.00)**	**(0.00)**	**(0.01)**	**(0.01)**
Basic shares outstanding	2,637,870	3,581,919	4,074,894	4,663,541	5,439,587	5,834,808	5,637,197	6,584,896	6,979,990	6,782,443	7,121,566
Diluted shares outstanding	2,637,870	3,581,919	4,074,894	4,663,541	5,439,587	5,834,808	5,637,197	6,584,896	6,979,990	6,782,443	7,588,281

Source: SEC filings, company press releases, and ROTH Capital Partners

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Disclosures:

Within the last twelve months, ROTH Capital Partners, or an affiliate to ROTH Capital Partners, has received compensation for investment banking services from Imugene Limited.

Shares of Imugene Limited may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

Each box on the Rating and Price Target History chart above represents a date on which an analyst made a change to a rating or price target, except for the first box, which may only represent the first note written during the past three years. **Distribution Ratings/IB Services** shows the number of companies in each rating category from which Roth or an affiliate received compensation for investment banking services in the past 12 month.

Distribution of IB Services Firmwide

			IB Serv./Past 12 Mos. as of 12/05/22	
Rating	**Count**	**Percent**	**Count**	**Percent**
Buy [B]	**299**	**78.68**	**207**	**69.23**
Neutral [N]	**49**	**12.89**	**25**	**51.02**
Sell [S]	**3**	**0.79**	**2**	**66.67**
Under Review [UR]	**29**	**7.63**	**14**	**48.28**

Our rating system attempts to incorporate industry, company and/or overall market risk and volatility. Consequently, at any given point in time, our investment rating on a stock and its implied price movement may not correspond to the stated 12-month price target.

Ratings System Definitions - ROTH employs a rating system based on the following:

Buy: A rating, which at the time it is instituted and or reiterated, that indicates an expectation of a total return of at least 10% over the next 12 months.

Neutral: A rating, which at the time it is instituted and or reiterated, that indicates an expectation of a total return between negative 10% and 10% over the next 12 months.

Sell: A rating, which at the time it is instituted and or reiterated, that indicates an expectation that the price will depreciate by more than 10% over the next 12 months.

Under Review [UR]: A rating, which at the time it is instituted and or reiterated, indicates the temporary removal of the prior rating, price target and estimates for the security. Prior rating, price target and estimates should no longer be relied upon for UR-rated securities.

Not Covered [NC]: ROTH does not publish research or have an opinion about this security.